<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02484508</url>
  </required_header>
  <id_info>
    <org_study_id>GL-15-01</org_study_id>
    <nct_id>NCT02484508</nct_id>
  </id_info>
  <brief_title>Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis</brief_title>
  <official_title>A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guizhou Bailing Group Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wangjing Hospital, China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guiyang College of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Guizhou Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guizhou Bailing Group Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous study showed that Guli capsule could suppress the adjuvant multiple arthritis; have
      inhibitory effect on carrageenan gelatinous and formaldehyde foot swelling; improve the
      symptom of osteoporosis patients; and improve pain and limited joint activities of rheumatoid
      patients.

      To further verify the clinical effect of Guli capsule in the treatment of knee
      osteoarthritis, the investigators perform this multi-center clinical study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Guli capsule, an approved Chinese patent drug, its main indications are for rheumatism,
      rheumatoid arthritis.

      Previous study showed that Guli capsule could suppress the adjuvant multiple arthritis; have
      inhibitory effect on carrageenan gelatinous and formaldehyde foot swelling; improve the
      symptom of osteoporosis patients; and improve pain and limited joint activities of rheumatoid
      patients.

      To further verify the clinical effect of Guli capsule in the treatment of knee
      osteoarthritis, the investigators perform this multi-center clinical study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Osteoarthritis index on the Western Ontario and McMaster Universities Osteoarthritis Index</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores on the Visual Analog Scale</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Guli capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guli capsule, the tested drug of this study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kangguzengsheng capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Kangguzengsheng capsule, a CFDA approved drug for articular genu osteoarthritis,is adopted as active comparator in this study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guli capsule</intervention_name>
    <description>Guli capsule,as the experimental drug,is taken 3 grains each time, 3 time per day</description>
    <arm_group_label>Guli capsule</arm_group_label>
    <other_name>GL capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kangguzengsheng capsule</intervention_name>
    <description>Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day</description>
    <arm_group_label>Kangguzengsheng capsule</arm_group_label>
    <other_name>KGZS capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages between 40 and 70 years, both gender

          -  Kellgren and Lawrence grades of I to III;

          -  The subjects volunteered participate in the study and complied with the regulations
             and signed the written consent voluntarily.

          -  Meet the following clinical and radiological criteria for diagnosis:

          -  Clinical criteria:

               1. most of the time have knee pain nearly a month

               2. bone fricative

               3. morning stiffness is less than or equal to 30 min

               4. age is more than or equal to 38 years

               5. bony enlargement. Who meet (1) + (2) or (1) + (4) + (5) can be diagnosed as knee
                  osteoarthritis.

          -  Radiological criteria:

               1. most of the time have knee pain nearly a month

               2. the X-ray showed osteophyte formation

               3. joint fluid examination confirmed with osteoarthritis

               4. age is more than or equal to 40 years

               5. morning stiffness is less than or equal to 30 min

               6. bone fricative. Meet (1) + (2) or (1) + (3) + (5) + (6) or (1) + (4) + (5) + (6).

        Exclusion Criteria:

          -  Patient with a history of allergy to similar constituents or chemical components of
             the drug;

          -  Patients with limited liver and kidney function;

          -  Patients with hematopoietic system disease;

          -  Patients with diabetes, Cushing's syndrome and other endocrine disorders;

          -  Patients with severe heart and brain disease;

          -  Patients with low immunity;

          -  Patients directly involved with the staff in the study;

          -  Women during pregnancy or lactation;

          -  Participating in other clinical studies or Participated in 3 months;

          -  The investigators judged who be unfit for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiheng Chen, MD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICMJE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weiheng Chen, MD Dr.</last_name>
    <phone>+861084739047</phone>
    <email>weihchenwj@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiuyi Chen, MD Dr.</last_name>
    <phone>+868515609789</phone>
    <email>jiuyichen@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wangjing Hospital, Chinese Academy of Traditional Chinese Medicine</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiheng Chen, MD Dr.</last_name>
      <phone>+861084739047</phone>
      <email>weihchenwj@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jiuyi Chen, MD Dr.</last_name>
      <phone>+868515609789</phone>
      <email>jiuychen77@sohu.com</email>
    </contact_backup>
    <investigator>
      <last_name>Weiheng Chen, MD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiuyi Chen, MD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min Huang, MD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2015</study_first_submitted>
  <study_first_submitted_qc>June 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2015</study_first_posted>
  <last_update_submitted>June 24, 2015</last_update_submitted>
  <last_update_submitted_qc>June 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Guli capsule</keyword>
  <keyword>knee osteoarthritis</keyword>
  <keyword>Changing of WOMAC and VAS score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

